AstraZeneca has halted a planned £200 million investment in its Cambridge research centre, pausing an expansion that was set to create around 1,000 new jobs. This move marks a retreat by the UK’s largest listed company from its development plans, reflecting wider concerns about the country’s business environment.
The funding, first announced in March 2024, is not proceeding at present, following AstraZeneca’s decision earlier this year to cancel a £450 million investment in its northern England vaccine manufacturing facility. The company cited cuts in government support as a key factor in that earlier withdrawal.
The pause in Cambridge investment comes shortly after U.S. pharmaceutical giant Merck & Co announced it was abandoning plans for a new research centre in London, attributing the decision to the challenges of operating within the UK’s current business climate.
When asked about AstraZeneca’s plans after Merck’s announcement, a company spokesperson confirmed that the Cambridge project was on hold.
“We constantly reassess the investment needs of our company and can confirm our expansion in Cambridge is paused. We have no further comment to make,” the spokesperson stated.
These developments show ongoing pressures facing the pharmaceutical industry in the UK, including rising operational costs and reduced government incentives. The sector is vital to the UK’s economy and reputation as a centre for innovation, especially in life sciences research hubs such as Cambridge.
While the government has introduced measures to support the industry—including tax reliefs and increased funding for research collaborations—scepticism remains about whether these will be sufficient to retain major global players.
The pharmaceutical industry’s reaction will be closely watched as policymakers consider further reforms to bolster the sector.